Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?

Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials?

IntroductionMedullary thyroid cancer (MTC) is a rare thyroid tumour whose management in advanced stages is challenging, despite effective therapeutic options having expanded in recent years. Proteasome inhibitors (PrIn) have shown the ability to improve patient outcomes, including survival and quali...

Full description

Bibliographic Details
Main Authors:	Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Erika Maria Grossrubatscher, Tullio Florio, Francesco Ferraù, Alessandro Veresani, Flaminia Russo, Annamaria Colao, Antongiulio Faggiano
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Endocrinology
Subjects:	medullary thyroid carcinoma proteasome inhibitors bortezomib carfilzomib ixazomib MG132
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1145926/full

Similar Items

Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment
by: Cassidy M. Van Stiphout, et al.
Published: (2022-09-01)

The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
by: Chun-fung Sin, et al.
Published: (2021-12-01)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
by: Sergio Di Molfetta, et al.
Published: (2021-04-01)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
by: Mariah L. Farrell, et al.
Published: (2018-05-01)

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
by: Erika Grossrubatscher, et al.
Published: (2020-10-01)

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
by: Michael A. Harris, et al.
Published: (2020-05-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01)

Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024-03-01)

Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
by: Sergio Di Molfetta, et al.
Published: (2022-02-01)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
by: John H. Chen, et al.
Published: (2017-06-01)

Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
by: Ioannis Petrakis, et al.
Published: (2023-12-01)

Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
by: Peter Tsvetkov, et al.
Published: (2015-09-01)

Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
by: Giuseppe Fanciulli, et al.
Published: (2022-08-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib‐based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients
by: Yuka Kawaji‐Kanayama, et al.
Published: (2022-02-01)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
by: Maiko Matsushita, et al.
Published: (2023-09-01)

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
by: Laure Maneix, et al.
Published: (2021-02-01)

Acute antibody-mediated rejection limited to medullary lesions in following ABO-incompatible living donor kidney transplantation
by: A Young Kim, et al.
Published: (2021-03-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
by: Giuseppe Fanciulli, et al.
Published: (2020-12-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Evaluation of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Systemic Immune–Inflammation Index (SII) as Potential Biomarkers in Patients with Sporadic Medullary Thyroid Cancer (MTC)
by: Roberta Modica, et al.
Published: (2023-06-01)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study
by: Man Shen, et al.
Published: (2022-06-01)

Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
by: David J. Sherman, et al.
Published: (2020-02-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
by: Diego Acosta-Alvear, et al.
Published: (2015-09-01)

Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches
by: Andrea Lania, et al.
Published: (2021-07-01)

Editorial—Special Issue: Foreword to the Special Issue on NIKE: Neuroendocrine Tumors, Innovation in Knowledge and Education
by: Antongiulio Faggiano, et al.
Published: (2021-07-01)

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
by: Grazia Raffaella Tundo, et al.
Published: (2022-02-01)

Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions
by: Yunzhou Fan, et al.
Published: (2021-02-01)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
by: Min Seung Lee, et al.
Published: (2021-02-01)

Activation of Serum/Glucocorticoid Regulated Kinase 1/Nuclear Factor-κB Pathway Are Correlated with Low Sensitivity to Bortezomib and Ixazomib in Resistant Multiple Myeloma Cells
by: Masanobu Tsubaki, et al.
Published: (2021-01-01)

Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms
by: Giuseppe Fanciulli, et al.
Published: (2023-12-01)

Sweet Syndrome Associated with Ixazomib
by: İrfan Yavaşoğlu, et al.
Published: (2021-08-01)

What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature
by: Elisa Giannetta, et al.
Published: (2022-09-01)

Topography of the medullary cone in coatimundi (Nasua nasua, Linnaeus 1766)
by: Guilherme Buzon Gregores, et al.
Published: (2010-06-01)

Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target
by: Roberta Modica, et al.
Published: (2022-11-01)